Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Orlaam (Levomethadyl Acetate Hydrochloride) Apr 2001

Audience: Addiction treatment specialists

Healthcare professionals are notified about serious cardiac adverse events, including QT prolongation and severe cardiac arrhythmia, associated with Orlaam (levomethadyl acetate HCl), a drug for opiate addiction treatment. Roxane Laboratories, Inc. has made important changes to the Orlaam label, adding a black box warning, and changes to the precautions, contraindications, and drug interactions sections.

[April 19, 2001 - Letter - Roxane Laboratories, Inc]

-
-